SEC Form SC 13G filed by Neurogene Inc.

11/12/24 10:32:12 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NGNE alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 NEUROGENE INC COMMON STOCK Cusip #64135M105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #64135M105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 731,771 Item 6: 0 Item 7: 731,801 Item 8: 0 Item 9: 731,801 Item 11: 5.632% Item 12: HC Cusip #64135M105 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 731,801 Item 8: 0 Item 9: 731,801 Item 11: 5.632% Item 12: IN Item 1(a). Name of Issuer: NEUROGENE INC Item 1(b). Address of Issuer's Principal Executive Offices: 535 W 24TH STREET, 5TH FLOOR NEW YORK, NY 10011 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 64135M105 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 731,801 (b) Percent of Class: 5.632% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 731,801 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of NEUROGENE INC. No one other person's interest in the COMMON STOCK of NEUROGENE INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC * IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of NEUROGENE INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $NGNE alert in real time by email

Date

Price Target

Rating

Analyst

6/27/2024

$65.00

Outperform

BMO Capital Markets

6/11/2024

$54.00

Outperform

Robert W. Baird

4/29/2024

$46.00

Outperform

Leerink Partners

3/21/2024

$61.00

Outperform

William Blair

SEC Form SC 13G filed by Neurogene Inc.

Chat with this insight

Recent Analyst Ratings for
$NGNE

$NGNE
Financials

Live finance-specific insights

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

$NGNE
SEC Filings

Neurogene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Neurogene Inc.

Neurogene Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$NGNE
Leadership Updates

Live Leadership Updates

Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

$NGNE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

BMO Capital Markets initiated coverage on Neurogene with a new price target

Robert W. Baird initiated coverage on Neurogene with a new price target

Leerink Partners initiated coverage on Neurogene with a new price target

$NGNE
Press Releases

Fastest customizable press release news feed in the world

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Neurogene Announces Oversubscribed $200 Million Private Placement

Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

$NGNE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$NGNE
Market Insights

Live Market Insights

$NGNE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form 4 filed by Director Woods Robert Keith

SEC Form 4 filed by Director Palekar Rohan

SEC Form 4 filed by Director Baffi Robert

Neurogene To Be Added To Russell 3000 Index, Effective At Open On Jul. 1

Neurogene shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a $65 price target.

BMO Capital Initiates Coverage On Neurogene with Outperform Rating, Announces Price Target of $65